Thromboprophylaxis given in Myeloma IX and Myeloma XI trials before VTE and type of thromboprophylaxis received if given (by induction chemotherapy)
| . | Myeloma IX . | Myeloma XI . | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVAD . | CTD . | MP . | CTDa . | Total . | CTD . | CRD . | CTDa . | CRDa . | KCRD . | Total . | ||||||||||||
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Thromboprophylaxis given | ||||||||||||||||||||||
| Yes | 44 | 27.7 | 18 | 16.7 | 3 | 16.7 | 17 | 20.5 | 82 | 22.3 | 130 | 79.8 | 132 | 82.0 | 93 | 84.5 | 93 | 80.9 | 85 | 75.2 | 533 | 80.5 |
| No | 114 | 71.7 | 90 | 83.3 | 15 | 83.3 | 64 | 77.1 | 283 | 76.9 | 32 | 19.6 | 27 | 16.8 | 17 | 15.5 | 21 | 18.3 | 28 | 24.8 | 125 | 18.9 |
| Missing | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 2 | 2.4 | 3 | 0.8 | 1 | 0.6 | 2 | 1.2 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 4 | 0.6 |
| Total | 159 | 100 | 108 | 100 | 18 | 100 | 83 | 100 | 368 | 100 | 163 | 100 | 161 | 100 | 110 | 100 | 115 | 100 | 113 | 100 | 662 | 100 |
| Thromboprophylaxis received (if given)* | ||||||||||||||||||||||
| Aspirin | NR | NR | NR | NR | NR | 39 | 28.9 | 46 | 34.3 | 42 | 43.3 | 39 | 41.1 | 19 | 21.6 | 185 | 33.7 | |||||
| Treatment-dose warfarin | 24 | 54.5 | 9 | 50.0 | 1 | 33.3 | 13 | 76.5 | 47 | 57.3 | 5 | 3.7 | 9 | 6.7 | 3 | 3.1 | 3 | 3.2 | 2 | 2.3 | 22 | 4.0 |
| LMWH | 16 | 36.4 | 9 | 50.0 | 2 | 66.7 | 4 | 23.5 | 31 | 37.8 | 88 | 65.2 | 76 | 56.7 | 51 | 52.6 | 52 | 54.7 | 64 | 72.7 | 331 | 60.3 |
| Other | 3 | 6.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 3.7 | 3 | 2.2 | 3 | 2.2 | 1 | 1.0 | 1 | 1.1 | 3 | 3.4 | 11 | 2.0 |
| Missing | 1 | 2.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Total | 44 | 100 | 18 | 100 | 3 | 100 | 17 | 100 | 82 | 100 | 135 | 100 | 134 | 100 | 97 | 100 | 95 | 100 | 88 | 100 | 549 | 100 |
| . | Myeloma IX . | Myeloma XI . | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVAD . | CTD . | MP . | CTDa . | Total . | CTD . | CRD . | CTDa . | CRDa . | KCRD . | Total . | ||||||||||||
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Thromboprophylaxis given | ||||||||||||||||||||||
| Yes | 44 | 27.7 | 18 | 16.7 | 3 | 16.7 | 17 | 20.5 | 82 | 22.3 | 130 | 79.8 | 132 | 82.0 | 93 | 84.5 | 93 | 80.9 | 85 | 75.2 | 533 | 80.5 |
| No | 114 | 71.7 | 90 | 83.3 | 15 | 83.3 | 64 | 77.1 | 283 | 76.9 | 32 | 19.6 | 27 | 16.8 | 17 | 15.5 | 21 | 18.3 | 28 | 24.8 | 125 | 18.9 |
| Missing | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 2 | 2.4 | 3 | 0.8 | 1 | 0.6 | 2 | 1.2 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 4 | 0.6 |
| Total | 159 | 100 | 108 | 100 | 18 | 100 | 83 | 100 | 368 | 100 | 163 | 100 | 161 | 100 | 110 | 100 | 115 | 100 | 113 | 100 | 662 | 100 |
| Thromboprophylaxis received (if given)* | ||||||||||||||||||||||
| Aspirin | NR | NR | NR | NR | NR | 39 | 28.9 | 46 | 34.3 | 42 | 43.3 | 39 | 41.1 | 19 | 21.6 | 185 | 33.7 | |||||
| Treatment-dose warfarin | 24 | 54.5 | 9 | 50.0 | 1 | 33.3 | 13 | 76.5 | 47 | 57.3 | 5 | 3.7 | 9 | 6.7 | 3 | 3.1 | 3 | 3.2 | 2 | 2.3 | 22 | 4.0 |
| LMWH | 16 | 36.4 | 9 | 50.0 | 2 | 66.7 | 4 | 23.5 | 31 | 37.8 | 88 | 65.2 | 76 | 56.7 | 51 | 52.6 | 52 | 54.7 | 64 | 72.7 | 331 | 60.3 |
| Other | 3 | 6.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 3.7 | 3 | 2.2 | 3 | 2.2 | 1 | 1.0 | 1 | 1.1 | 3 | 3.4 | 11 | 2.0 |
| Missing | 1 | 2.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Total | 44 | 100 | 18 | 100 | 3 | 100 | 17 | 100 | 82 | 100 | 135 | 100 | 134 | 100 | 97 | 100 | 95 | 100 | 88 | 100 | 549 | 100 |
Not mutually exclusive.